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Abstract
Background: Unmyelinated primary afferent nociceptors are commonly classified into two main functional types:
those expressing neuropeptides, and non-peptidergic fibers that bind the lectin IB4. However, many small diameter
primary afferent neurons neither contain any known neuropeptides nor bind IB4. Most express high levels of
vesicular glutamate transporter 2 (VGluT2) and are assumed to be glutamatergic nociceptors but their terminations
within the spinal cord are unknown. We used in vitro anterograde axonal tracing with Neurobiotin to identify the
central projections of these putative glutamatergic nociceptors. We also quantitatively characterised the spatial
arrangement of these terminals with respect to those that expressed the neuropeptide, calcitonin gene-related
peptide (CGRP).
Results: Neurobiotin-labeled VGluT2-immunoreactive (IR) terminals were restricted to lamina I, with a medial-to-
lateral distribution similar to CGRP-IR terminals. Most VGluT2-IR terminals in lateral lamina I were not labeled by
Neurobiotin implying that they arose mainly from central neurons. 38 ± 4% of Neurobiotin-labeled VGluT2-IR
terminals contained CGRP-IR. Conversely, only 17 ± 4% of Neurobiotin-labeled CGRP-IR terminals expressed
detectable VGluT2-IR. Neurobiotin-labeled VGluT2-IR or CGRP-IR terminals often aggregated into small clusters or
microdomains partially surrounding intrinsic lamina I neurons.
Conclusions: The central terminals of primary afferents which express high levels of VGluT2-IR but not CGRP-IR
terminate mainly in lamina I. The spatial arrangement of VGluT2-IR and CGRP-IR terminals suggest that lamina I
neurons receive convergent inputs from presumptive nociceptors that are primarily glutamatergic or peptidergic.
This reveals a previously unrecognized level of organization in lamina I consistent with the presence of multiple
nociceptive processing pathways.
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Background
Most primary afferent neurons in dorsal root ganglia
(DRG) are considered to use glutamate as their fast
excitatory transmitter, [1-3], although some may use
aspartate instead [4-6]. Many smaller DRG neurons,
including nociceptors, express high levels of neuropep-
tides, usually both calcitonin gene-related peptide
(CGRP) and substance P [7-12] or bind the lectin, IB4
[13-15]. The peptidergic neurons span a range of
nociceptive modalities, including those associated with
transient receptor potential cation channel subfamily V
(TRPV1) receptor activation in response to noxious heat
or inflammation, for example [16,17].
Early microscopic identification of putative glutama-
tergic primary afferent neurons attempted to directly
localize glutamate or glutaminase, for example
[2,6,18-20], which also exist in metabolic pools not
directly associated with neurotransmission. The subse-
quent discovery of the vesicular glutamate transporters
(VGluTs) enabled specific immunolabeling of presump-
tive glutamatergic neurons based on their expression of
VGluTs [21-24]. Thus, VGluT1 is expressed mainly by
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senting myelinated mechanoceptors, whereas small dia-
meter primary afferent neurons, including unmyelinated
nociceptors, express VGluT2 to varying degrees
[23,25,26].
VGluT2 is considered to be expressed at low levels in
most peptidergic nociceptors [24,27-31]. However, there
is a significant population of small diameter neurons,
presumably nociceptors, that express high levels of
VGluT2 in their soma but no known neuropeptide nor
bind IB4 [30]. It has proven difficult to positively iden-
tify the central terminations of these VGluT2-immunor-
eactive (IR) nociceptors mainly because (1) the level of
immunolabeling in their terminals may be low; and (2)
these terminals are greatly outnumbered by intrinsic
spinal terminals that express strong VGluT2-IR
[24,26-28,30]. Therefore, we developed an in vitro tech-
nique for anterograde axonal tracing of dorsal roots
using Neurobiotin which labels unmyelinated as well as
myelinated sensory fibers entering the dorsal horn. By
combining Neurobiotin tracing of dorsal roots with
immunohistochemical localization of VGluT2, we have
distinguished the central projections of small diameter
glutamatergic primary afferents from intrinsic VGluT2-
IR endings in mouse lumbar spinal dorsal horn. Using
three-dimensional (3D) quantitative confocal micro-
scopy, we have compared the organization of central
terminals of the subset of VGluT2-IR afferents which
lack CGRP-IR (and IB4-binding) with those of afferents
containing CGRP-IR. Our data show that a discrete
population of putative non-peptidergic glutamatergic
nociceptors terminate in lamina I that can be distin-
guished from afferent terminals expressing neuropep-
tides. Furthermore, lamina I was found to consist of a
series of microdomains that are enriched in terminals
which are predominantly either peptidergic or presump-
tive glutamatergic nociceptors.
Results
Distribution of VGluT2- and CGRP-immunoreactive
terminals in the dorsal horn
Wide-field multiple-labeling immunofluorescence at
lumbar segments of mouse spinal cord showed that
VGluT2-IR varicosities were abundant throughout the
spinal gray matter (Figure 1A), consistent with prior
observations [24,25,27-30,32]. The VGluT2 immunola-
beling clearly distinguished spinal regions containing
terminals with different labeling intensities. As has been
previously reported, intensely labeled VGluT2-IR term-
inals were particularly dense in lamina I and in the lat-
eral spinal nucleus, with a dense band of VGluT2
terminals also evident in lamina II [28-30]. Within
lamina I, VGluT2-IR varicosities were most abundant
laterally, where they formed a band extending deeper
into the dorsal horn compared with medial lamina I. As
reported previously [7,28,30] CGRP-IR varicosities were
prominent across lamina I and in the central region of
lamina IV-V (Figure 1B).
High-magnification examination of lamina I sections
double-labeled for VGluT2-IR and CGRP-IR suggested
that clusters of VGluT2-IR varicosities and CGRP-IR
varicosities often occupied small mutually exclusive
regions or domains. Fourier transformation and spatial
filtering of images to identify large-scale features of the
VGluT2-IR and CGRP-IR labeling in lamina I confirmed
that domains enriched for VGluT2-IR were interspersed
with domains enriched for CGRP-IR, with limited over-
lap, mostly in lateral domains (Figure 1C). Observation
of consecutive transverse sections showed rostral-caudal
variation in the precise medio-lateral location of the
VGluT2-IR-rich and CGRP-IR-rich domains. Therefore
in order to demonstrate the overall organisation of these
domains, Fourier transformed images from 3 animals
were aligned and merged (Figure 1D-E). The resultant
composite image also showed that VGluT2-IR-enriched
domains tended to be superficial to CGRP-IR-enriched
domains, especially in lateral lamina I (Figure 1C-E). An
additional analysis of Fourier transformed images from
consecutive sections from one animal confirmed that
domains enriched in VGluT2-IR were more prominent
in the lateral regions of lamina I, compared with CGRP-
IR-enriched domains (two-way ANOVA, significant
interaction between label and region: F(1,159) =6 . 1 ,p=
0.02; n = 163 domains from five sections taken from
lumbar spinal segment L3). There was also a significant
positive correlation between the medial-to-lateral loca-
tion of the VGluT2-IR domains and their size (r = 0.4, p
< 0.001; n = 102 domains from five sections at L3).
Anterograde axonal tracing of primary afferent fibers
To distinguish VGluT2-IR terminals of primary afferent
origin in the dorsal horn from those of intrinsic origin,
VGluT2 immunolabeling was combined with antero-
grade axonal tracing from the dorsal roots with Neuro-
biotin. Neurobiotin always labeled fibers projecting into
the dorsal horn and dorsal funiculus. The following
observations are taken from 6 preparations showing uni-
formly extensive labeling with Neurobiotin as well as
strong immunoreactivity for VGluT2 and CGRP.
Neurobiotin labeled large diameter fibers (presump-
tive myelinated mechanoreceptors) and fine varicose
fibers (presumptive Aδ- and C-fibers) throughout the
ipsilateral dorsal horn. Fine varicose fibers labeled with
Neurobiotin were particularly dense in the superficial
dorsal horn. A plexus of large and small diameter
Neurobiotin-labeled fibers ramified in the deep dorsal
horn corresponding to laminae III-IV. Some labeled
fibers extended into the ventral horn. Occasional
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lus (Figure 2A-C).
In the superficial dorsal horn, Neurobiotin-labeled pri-
mary afferent fibers extended at least three spinal
segments cranial and at least two spinal segments caudal
to the dorsal root where tracer was applied, as expected
from previous observations using other tracing methods
[33-35]. Neurobiotin labeling of fibers in the deep dorsal
Figure 1 VGluT2 and CGRP immunoreactivity in the dorsal horn of L3 spinal cord. A: VGluT2-IR labeling occurs throughout the gray matter
but labels a dense band of terminals in lamina I which is more prominent laterally. VGluT2-IR is also prominent in the lateral spinal nucleus and
lamina II. B: Strong CGRP-IR occurs across lamina I but is especially dense medially. Some CGRP-IR fibers project deeper within the dorsal horn
around the mid regions of laminae III-IV. C: Images in (A) and (B) band-pass filtered by Fast Fourier Transformation (FFT), thresholded and
merged to reveal larger scale domain organization of the VGluT2-IR (red) and CGRP-IR (green) terminals in lamina I. Domains enriched with
VGluT2-IR or CGRP-IR terminals are interspersed with domains containing both types of terminals (yellow). VGluT2-IR domains are superficial to
CGRP-IR domains in lateral dorsal horn. D-E: Intensity plots of merged and aligned FFT-filtered images of L3 spinal cord from three animals to
show the overall organization of domains enriched for VGluT2-IR or CGRP-IR. The height of the peak represents the mean labeling intensity of
the domain; red, VGluT-IR; green, CGRP-IR. D: Ventral view. E: Dorsal view. Domains enriched in VGluT2-IR tend to lie more dorsally, especially in
lateral lamina I where it abuts the lateral spinal nucleus. Domains enriched in CGRP-IR tend to lie more deeply, especially in medial lamina I.
Scale bar in A represents 100 μm and applies to all panels. The axes indicate the orientation of the transverse sections: D; dorsal, V; ventral, M;
medial, L; lateral, and for the 3D plots, I; intensity in arbitrary grayscale units. The approximate location of the superficial laminae are marked in A
and B: lamina I; I, lamina II; II, and lamina III; III. The location of the lateral spinal nucleus is also indicated; lsn.
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Page 3 of 17Figure 2 Central terminals of primary afferent fibers detected by anterograde axonal tracing with Neurobiotin. A: Neurobiotin labeling in
L3 spinal cord after application of the tracer to L3 dorsal root. There is extensive Neurobiotin labeling of axons in Lissauer’s Tract, large and fine-
diameter varicose fibers in the dorsal horn (boxed region enlarged in B) and extending into the ventral horn (boxed region enlarged in C). D:
Neurobiotin labeling in L2 dorsal horns after application of the tracer to L3 dorsal root on one side of the spinal cord and all six lumbar dorsal roots
on the other side. Tracing from multiple roots produces more labeled fibers in the dorsal horn but with a comparable distribution compared with
labeling from a single root. E: Neurobiotin labeling in L1 dorsal horn after application of the tracer to the ipsilateral L3 dorsal root. There is strong
labeling in the dorsal funiculus, but labeling can still be seen in lamina I. The same section is labeled for IB4-binding (F), CGRP-IR (G), VGluT2-IR (H);
overlaid image (I; Neurobiotin; green, IB4; orange, CGRP; red, VGluT2; blue). Representative images from 3 separate experiments; A-C, D, and E-I.
Scale bar represents 200 μmi nA, D and E,2 0μmi nC (also applies to B), and 100 μmi nI (also applies to F-H). Lissauer’s Tract; LT, dorsal horn; dh,
ventral horn; vh, dorsal funiculus; df, central canal; cc, lateral spinal nucleus; lsn, lamina I; I, lamina II; II, lamina III; I.
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immediately caudal to the level of the traced dorsal
root. In all experiments, subsets of Neurobiotin-labeled
primary afferent terminals also were labeled for
VGluT2-IR, CGRP-IR or IB4-binding (Figure 2E-I). As
expected from previous studies [13-15,25,30], IB4-bind-
ing fibers terminated deeper within the dorsal horn than
the CGRP-IR fibers; they were not investigated further
here. Neurobiotin labeling was not observed in the lat-
eral spinal nucleus in any experiment, consistent with
earlier lesioning studies that concluded there is no direct
primary afferent projection to this area [36].
Simultaneous application of Neurobiotin to all six lum-
bar dorsal roots (L1-L6) labeled more primary afferent
terminals compared with Neurobiotin application to only
the L3 dorsal root (simultaneous L1-L6 application: Neu-
robiotin labeled 52 ± 8% of CGRP-IR terminals at L3; n =
3; only L3 application: Neurobiotin labeled 36 ± 4% of
CGRP-IR terminals at L3; n = 3). However, the relative
distributions of total Neurobiotin-labeled fibers, Neuro-
biotin-labeled CGRP-IR terminals and Neurobiotin-
labeled VGluT2-IR terminals across the superficial dorsal
horn did not differ between experiments, thereby permit-
ting combined analysis of all six of these experiments.
VGluT2-IR primary afferent fibers terminate
predominantly in outer lamina I
High resolution confocal microscopy showed that the
band of VGluT2-IR terminals in upper lamina I included a
range of terminal sizes and labeling intensities, with many
intensely VGluT2-IR labeled varicosities. The second band
of VGluT2-IR varicosities in outer lamina IIcomprisedV-
GluT2-IR varicosities which were overall less dense and
less intensely labeled than those in upper lamina I. Consis-
tent with low magnification studies by us (Figure 2) and
others [28-30], VGluT2-IR varicosities were also distribu-
ted at lower density throughout the remaining spinal gray
matter, including inner lamina I and inner lamina II.
Single optical slice and 3D colocalization analysis of
confocal z-stacks spanning lamina I and II (from Lis-
sauer’s Tract to the outer border of lamina III) showed
that Neurobiotin-labeled VGluT2-IR varicosities
occurred predominantly in outer lamina I (Figure 3, see
also Figure 4 and Figure 5). Whilst Neurobiotin-labeled
VGluT2-IR varicosities were common in upper lamina I,
many VGluT2-IR varicosities in lamina I lacked Neuro-
biotin labeling (Figure 3A-F). Terminals which con-
tained the tracer were scarce in inner lamina I and
among the band of VGluT2-IR terminals in outer
lamina II. Only occasional VGluT2-IR terminals in inner
lamina II contained Neurobiotin. These terminals were
mostly of a large size and only weakly labeled for
VGluT2-IR compared with Neurobiotin-labeled
VGluT2-IR terminals in lamina I (Figure 3A-C, G-I).
VGluT2-IR terminals lacking Neurobiotin labeling pre-
sumably included both the terminals of intrinsic spinal
neurons as well as VGluT2-IR primary afferent terminals
which did not take up Neurobiotin (see below).
Most VGluT2-IR terminals of primary afferent origin
lacked detectable expression of CGRP-IR. Conversely,
most CGRP-IR terminals lacked detectable expression of
VGluT2-IR
High resolution confocal z-stacks from medial, mid and
lateral regions of the outer 60 μm of the dorsal horn
(including all of lamina I) were analysed by examination
of single optical slices and by using 3D colocalization to
compare the spatial distributions of Neurobiotin-labeled
VGluT2-IR and Neurobiotin-labeled CGRP-IR terminals
(Figure 4, 5, 6). This region included almost all Neuro-
biotin-labeled VGluT2-IR terminals (Figure 3).
Comparison of Neurobiotin-labeled VGluT2-IR term-
inals and CGRP-IR terminals by high resolution confocal
microscopy of the superficial dorsal horn revealed that the
central terminals of these two populations of primary
afferents were mostly discrete from one another. Many
VGluT2-IR terminals, across a range of VGluT2-IR label-
ing intensities and varicosity sizes, lacked detectable CGRP
expression, as shown by analysis of individual optical sec-
tions (Figure 4) and by comprehensive 3D colocalisation
analysis of confocal z-stacks (Figure 5, 6). Similarly most
CGRP-IR terminals lacked detectable VGluT2-IR expres-
sion (Figure 4, 5, 6). Nevertheless, a small proportion of
Neurobiotin-labeled primary afferent terminals did express
both VGluT2-IR and CGRP-IR. Some Neurobiotin-labeled
terminals with strong VGluT2-IR labeling showed only
weak CGRP-IR labeling, and vice versa. In some cases, dif-
ferent intensities of VGluT2-IR and CGRP-IR occurred
within the same Neurobiotin-labeled varicosity, as has
been previously reported [27].
Many, but not all, CGRP-IR terminals in lamina I at the
L3 spinal level were labeled with Neurobiotin. Across the
medial, mid and lateral regions spanning lamina I which
were analysed for the six experiments, 44 ± 4% of CGRP-
IR terminals were found to contain the tracer (Table 1).
Since all CGRP-IR terminals are believed to be of pri-
mary afferent origin, the presence of CGRP-IR terminals
without Neurobiotin label indicated that not all afferent
fibers were labeled with this procedure. Primary afferent
terminals within the L3 dorsal horn which originate
from DRG at other, untraced, segmental levels would
also remain unfilled by Neurobiotin.
Quantitative 3D analysis of the non uniform projections
of VGluT2-IR and CGRP-IR primary afferents to lamina I
Quantitative 3D analysis of confocal data sets confirmed
our wide-field observations. Averaged across lamina I,
total CGRP-IR terminals were more abundant than total
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normalized volume; VGluT2-IR terminals: 41.9 ± 7.7%
normalized volume). Nevertheless, the highest density of
total VGluT2-IR terminals occurred in lateral lamina I,
where they outnumbered total CGRP-IR terminals
(lateral region VGluT2-IR terminals: 62.2 ± 14.4% nor-
malized volume; lateral region CGRP-IR terminals: 33.3
± 6.2% normalized volume; see Figure 6). In contrast,
the highest density of CGRP-IR terminals occurred in
mid lamina I.
Figure 3 Identification of the central terminals of VGluT2-expressing primary afferents. High resolution confocal microscope imaging was
performed to identify VGluT2-IR terminals labeled with Neurobiotin and therefore of primary afferent origin. Images are a projection of 3 optical
z-sections captured 0.25 μm apart from the mid superficial dorsal horn at L3 spanning lamina I and II. A: Neurobiotin (green), after application to
all 6 lumbar dorsal roots. B: VGluT2-IR (magenta). C: merged image of A and B, with terminals containing both Neurobiotin and VGluT2-IR
appearing whiter. VGluT2-IR terminals labeled with Neurobiotin are abundant in upper lamina I (arrows, and see enlargements of boxed area in
C; D-F). VGluT2-IR terminals without Neurobiotin also are present in lamina I. A second band of dense VGluT2-IR terminals is visible in outer
lamina II, but none are labeled with Neurobiotin in this example. VGluT2-IR varicosities are overall less dense in inner lamina II. Few VGluT2-IR
varicosities in inner lamina II contain Neurobiotin: they are mostly large varicosities only weakly labeled with VGluT2-IR (arrowheads; and see
enlargements of boxed area in C; G-I). Scale bar in C represents 10 μm and also applies to A and B. Scale bar in I represents 5 μm and also
applies to D-H. LT; Lissauer’s Tract, I; lamina I, IIo; outer lamina II, Iii; inner lamina II.
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Page 6 of 17Figure 4 Expression of VGluT2 in Neurobiotin-labeled primary afferent terminals. High resolution confocal microscope imaging was
performed to identify VGluT2-IR terminals labeled with Neurobiotin and therefore of primary afferent origin. Images represent a projection of 3
optical z-sections taken 0.25 μm apart. A: Neurobiotin (green), B: VGluT2-IR (magenta), C: CGRP-IR (red) and D: merged image. Varicosities
containing both Neurobiotin and VGluT2-IR were common in upper lamina I, and many lacked CGRP-IR (arrows). Conversely, many of the
varicosities containing both Neurobiotin and CGRP-IR lacked VGluT2-IR (arrowheads). Occasionally both VGluT2-IR and CGRP-IR occurred within
the same Neurobiotin-labeled varicosity (short arrows with asterisks). The arrow with a single asterisk shows an example of a Neurobiotin-labeled
varicosity with strong VGluT2-IR and weak CGRP-IR. The arrow with the double asterisks shows an example of a Neurobiotin-labeled varicosity
with weak VGluT2-IR and strong CGRP-IR. Varicosities labeled with both Neurobiotin and VGluT2-IR were scarce below lamina I. Panels E-H and I-
L are enlargements of regions indicated by white boxes in D. Scale bar represents 10 μm in D (also applies to panels A-C) and 5 μm in L (also
applies to panels E-K). LT; Lissauer’s Tract, I; lamina I, IIo; outer lamina II, Iii; inner lamina II.
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Page 7 of 17Figure 5 Identification of VGluT2-IR and CGRP-IR afferents in lamina I using 3D co-localization with Neurobiotin labeling. A: Montage
of maximum projections of confocal image stacks (11 images per stack; z-interval = 1 μm) showing primary afferents labeled with Neurobiotin
(green) and terminals labeled for VGluT2-IR (magenta) and CGRP-IR (red). Representative locations for high resolution analyses of medial, mid and
lateral regions are indicated by white boxes. B-D: maximum projections of high resolution confocal image stacks (41 images per stack; 80 × 80
μm; z-interval = 0.5 μm) from medial (B), mid (C) and lateral (D) regions of lamina I (boxed areas in A). E-G: 3D reconstructions of data from
image stacks in B-D, respectively, showing all Neurobiotin-labeled fibers (green), VGluT2-IR terminals (purple) and CGRP-IR terminals (red). H-J: 3D
colocalization showing only Neurobiotin-labeled terminals containing VGluT2-IR (blue) or CGRP-IR (yellow). Scale bar represents 100 μmi nA.
Scale bar in D represents 10 μm and applies to panels B-J. LT; Lissauer’s Tract, I; lamina I, IIo; outer lamina II.
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in lamina I followed that of CGRP-IR terminals, with
highest density in the mid region. Neurobiotin-labeled
CGRP-IR terminals were more abundant than Neuro-
biotin-labeled VGluT2-IR terminals in each of the three
lamina I regions (Figure 6).
The proportion of CGRP-IR terminals labeled with
Neurobiotin was comparable across all three regions of
lamina I (44 ± 4%; Figure 6, Table 1). However, the pro-
portion of VGluT2-IR terminals labeled with Neurobio-
tin was significantly lower in the lateral region
compared to mid and medial regions of lamina I (two-
way ANOVA with Bonferroni corrections; p ≤ 0.05),
indicating that lateral lamina I contained predominantly
intrinsic VGluT2-IR terminals (Figure 6, Table 1). This
interpretation was confirmed by comparing the Neuro-
biotin labeling efficiency of CGRP-IR and VGluT2-IR
terminals across lamina I. In medial and mid regions,
the proportion of VGluT2-IR terminals labeled with
Neurobiotin compared with the proportion of CGRP-IR
terminals labeled with Neurobiotin was 70 ± 6%, whilst
in lateral regions, this ratio was only 28 ± 7% (Table 1).
Figure 6 Distribution of anterogradely-labeled VGluT2-IR and CGRP-IR terminals across lamina I. Quantification of total and
anterogradely-labeled VGluT2 and CGRP immunoreactivity in medial, mid and lateral regions of lamina I. 3D colocalisation analysis and volume
quantification was performed on regions of interest spanning lamina I within the high resolution confocal z-stacks at each location as shown in
Figure 4. Analysed regions extended from the boundary of Lissauer’s Tract and lamina I to a depth of 60 μm within the dorsal horn, which
spanned the region where anterogradely-labeled VGluT2-IR terminals were observed. The dimensions of each analysed region was 80 × 60 × 10
μm. Values are expressed as relative volumes normalized against the maximum volume of CGRP-IR terminals in any of the regions for each
dorsal horn section. The relative proportion of Neurobiotin-labeled VGluT2-IR terminals compared with the total volume of VGluT2-IR terminals
was significantly less in lateral regions of lamina I compared with medial and mid regions of lamina I (asterisk: p ≤ 0.05 for this comparison). The
relative proportion of Neurobiotin-labeled CGRP-IR terminals compared with the total volume of CGRP-IR terminals was consistent across all
three regions. Two-way ANOVA with Bonferroni post-hoc comparisons; n = 6 sections from 4 animals.
Table 1 Neurobiotin labeling of VGluT2-IR and CGRP-IR terminals in lamina I
Medial Mid Lateral Overall
Neurobiotin-labeled terminals with CGRP-IR as proportion of volume of total CGRP-IR terminals 37 ± 10% 53 ± 7% 42 ± 6% 44 ± 4%
Neurobiotin-labeled terminals with VGluT2-IR as proportion of volume of total VGluT2-IR terminals 26 ± 10% 39 ± 10% 13 ± 4%* 26 ± 4%
Neurobiotin-labeled VGluT2-IR terminals as proportion of Neurobiotin-labeled CGRP-IR terminals 69 ± 12% 70 ± 9% 28 ± 7%* 56 ± 4%
The proportion of VGluT2-IR terminals which were labeled with Neurobiotin as well as the ratio of Neurobiotin-labeled VGluT2-IR terminals compared to
Neurobiotin-labeled CGRP terminals were significantly lower in lateral lamina I compared to medial and mid lamina I (two-way ANOVA with Bonferroni
corrections using 95% confidence limits; p < 0.05, indicated by asterisks). Analysis of L3 spinal cord sections, n = 6 animals.
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IR
Throughout lamina I, less than half (38 ± 4%) of Neuro-
biotin-labeled VGluT2-IR terminals co-expressed
CGRP-IR (Table 2, Figure 6). Less than 20% of all Neu-
robiotin-labeled CGRP-IR terminals contained detect-
able VGluT2-IR (Table 2, Figure 6). The highest density
of Neurobiotin-labeled terminals colocalizing both
VGluT2-IR and CGRP-IR occurred in the mid region of
lamina I (10.0 ± 4.0% of Neurobiotin-labeled terminals;
Figure 6).
Clustered arrangement of VGluT2-IR and CGRP-IR
terminals in lamina I
Analysis of 3D confocal data sets confirmed wide-field
image analyses indicating that VGluT2-IR terminals and
CGRP-IR terminals commonly formed clusters within
lamina I. Such clusters of terminals appeared to sur-
round or abut spaces that contained unlabeled nerve
cell bodies (Figure 5B-G). The respective subsets of
VGluT2-IR and CGRP-IR terminals which were Neuro-
biotin labeled also formed clusters surrounded spaces
that contained unlabeled nerve cell bodies (Figure 5H-J).
Cluster analysis of the 3D center of mass coordinates of
3899 Neurobiotin-labeled terminals across lamina I
showed that VGluT2-IR terminals and CGRP-IR term-
inals tended to be clustered together more than would
be expected for a random distribution (Figure 7). All
clusters detected this way contained both terminals
which were VGluT2-IR and terminals which were
CGRP-IR. However, 35% of clusters were significantly
enriched in either VGluT2-IR or CGRP-IR terminals (X
2
tests and analysis of residuals, p < 0.05; hierarchical
cluster analysis using 15 random seed points). Most
clusters also contained a small number of Neurobiotin-
labeled terminals that co-expressed both VGluT2-IR
and CGRP-IR (Figure 7C).
Discussion
VGluT2-IR primary afferents project to lamina I
We have positively identified and mapped the distribu-
tion of the central terminals of non-peptidergic
VGluT2-expressing primary afferents in mouse lumbar
spinal cord. These terminals were mostly restricted to
lamina I, and only occasionally observed in lamina II,
where IB4-binding small-diameter afferent terminals
project. Therefore we also compared the distribution of
VGluT2-expressing primary afferents with that of pepti-
dergic primary afferents in lamina I. Previous studies
have shown that VGluT2-IR labels a subpopulation of
cell bodies within DRG, including neurons of both small
(cross sectional area < 300 μm
2) and medium (cross sec-
tional area 300-600 μm
2)s o m as i z e[ 2 6 , 3 0 ] .O n l ys o m e
of these VGluT2-IR cell bodies, whether small or med-
ium-sized, co-express CGRP [26,30]. Based on the pre-
dominant projection of fine diameter VGluT2-
expressing primary afferents into lamina I, it is most
probable that the non-peptidergic VGluT2-IR neurons
include a class of unmyelinated or lightly myelinated
nociceptors [27]. These non-peptidergic VGluT2-IR pri-
mary afferent terminals also may include non-nocicep-
tive Aδ and C-fibers such as innocuous thermal and
mechanical afferents.
The central terminals of these putative glutamatergic
nociceptors were largely restricted to the outer 60 μm
of lamina I. Their medial-to-lateral distribution across
lamina I was not different overall from the projection of
CGRP-IR afferents into lamina I. In contrast, the total
density of all VGluT2-IR terminals was much higher in
the lateral regions of lamina I. Most lateral VGluT2-IR
terminals were not labeled by anterograde tracing from
the dorsal roots and therefore they are most likely
derived from central neurons. The high ratio of intrinsic
to primary afferent VGluT2-IR terminals in the dorsal
horn is consistent with observations showing minimal
depletion of VGluT2-IR from the dorsal horn following
dorsal rhizotomy in rats [25,28,29] or selective knock-
out of VGluT2 expression in nociceptors of mice [26].
Several previous studies have reported that VGluTs
are either undetectable or present at very low levels in
most small diameter peptidergic afferents and their cen-
tral projections, in both mice [28,32] and rats
[19,24,25,27-29,31,37]. Similarly, immunoreactivity to
the amino acids themselves is low or undetectable in
the soma of many peptidergic afferents [6]. Nevertheless,
more recent reports find that almost all mouse DRG
neurons which express CGRP-IR or bind IB4 do also
express VGluT2 at some level and are functionally glu-
tamatergic [26,38]. Regardless of these apparent differ-
ences, all studies have illustrated significant VGluT2
Table 2 Colocalization of VGluT2-IR and CGRP-IR in Neurobiotin-labeled terminals across lamina I
Medial Mid Lateral Overall
Neurobiotin-labeled VGluT2-IR terminals with CGRP-IR
† 39 ± 7% 44 ± 8% 32 ± 8% 38 ± 4%
Neurobiotin-labeled CGRP-IR terminals with VGluT2-IR
‡ 7 ± 2% 20 ± 7% 24 ± 10% 17 ± 4%
†Neurobiotin-labeled VGluT2-IR terminals with CGRP-IR as a proportion of total Neurobiotin-labeled VGluT2 terminals in lamina I by volume.
‡Neurobiotin-labeled CGRP-IR terminals with VGluT2-IR as a proportion of total Neurobiotin-labeled CGRP terminals in lamina I by volume.
Analysis of L3 spinal cord, n = 6 animals.
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Page 10 of 17expression in a population of small-medium DRG neu-
rons which lack CGRP and IB4-binding, whilst finding
only low or undetectable levels of VGluT2-IR in the
central terminals of many peptidergic primary afferents.
Our data have confirmed that the central terminals of
anterogradely-labeled VGluT2-expressing terminals in
C57/Bl6 mice are mostly distinct from IB4-binding
terminals, and that only a small proportion of anterogra-
dely-labeled afferent terminals in lamina I contain both
CGRP-IR and detectable VGluT2-IR. Nevertheless,
around 17% of CGRP-IR terminals in the dorsal horn
also contained detectable VGluT2-IR. Therefore, this
combination of labels identifies three potential neuro-
chemical phenotypes within small diameter afferents
projecting to lamina I: those with CGRP-IR, those with
VGluT2-IR, and those with both (cf rat DRG: [6]). Most
CGRP-IR projections in lamina I would be expected also
to contain substance P [30]. No other peptides are
known to be expressed by the VGluT2-IR afferents that
lack CGRP-IR.
Recently, several populations of small-diameter pri-
mary afferents have been described that neither express
neuropeptides nor bind IB4, including most transient
receptor potential cation channel subfamily M
(TRPM8)-expressing nociceptors [39,40], some TRPV1-
expressing nociceptors [41], and small subpopulations of
Mrgprd-expressing and TRP Subfamily A (TRPA1)-
expressing nociceptors [42]. Given the recent demon-
stration of widespread expression of VGluT2 in small
diameter afferents [26,38], we predict that the non-
peptidergic VGluT2-IR neurons we have identified must
include at least some of these populations. Taken
together, these studies demonstrate that the commonly
used binary classification of small diameter nociceptors
as either peptide-expressing or non-peptidergic IB4 lec-
tin-binding neurons is insufficient to accommodate the
high degree of heterogeneity of small-diameter afferents
(for further critique of nociceptor classification, see
[17]).
There is considerable functional evidence that gluta-
mate mediates fast synaptic transmission from the great
majority of primary afferents. In contrast, neuropeptide
transmitters such as substance P and CGRP are thought
to have mainly a modulatory role, enhancing the excit-
ability of the second order neurons, and therefore
require the co-release of an excitatory amino acid in
order to excite second order neurons in the dorsal horn.
Indeed a recent study in mice in which the VGluT2
gene was selectively ablated in the majority of nocicep-
tors demonstrated that responses to acute noxious heat,
mechanical and chemical stimuli, as well as heat hyper-
algesia induced by injury or neuropathic pain, are
dependent on VGluT2-dependent glutamate transmis-
sion [26]. Whilst the usual interpretation is that peptides
and glutamate may be co-released from the same affer-
ent neuron, functional studies to date do not preclude
the possibility that peptide and amino acid release may
occur simultaneously from different afferent neurons
w h i c hc o n v e r g eo nl a m i n aIn e u r o n s .T h e r ei sp h a r m a -
cological evidence consistent with the independent
Figure 7 Cluster analysis of anterogradely-labeled VGluT2-IR and CGRP-IR terminals in lamina I. The 3D center of mass coordinates were
calculated for the Neurobiotin- and immuno-labeled terminals from 3D confocal data sets for medial, mid and lateral lamina I from one animal.
The coordinates were analysed by hierarchical cluster analysis with SPSS. The data set shown here is from medial lamina I. A: Neurobiotin-
labeled terminals with VGluT2-IR; B: Neurobiotin-labeled terminals with CGRP-IR; C: Neurobiotin-labeled terminals with both VGluT2-IR and CGRP-
IR. Each statistically-determined cluster is assigned a different color. The red and dark green clusters at the dorsal edge of the field are
dominated by VGluT2-IR terminals (ratio of VGluT2:CGRP terminals is about 2:1 in each cluster), whilst the orange and yellow clusters along the
ventral edge of the field are dominated by CGRP-IR terminals (ratio of CGRP:VGluT2 terminals is about 2:1 in each cluster; X
2 test and analysis of
residuals, p < 0.05 in each case). The axes indicate the orientation of the data set: D; dorsal, V; ventral, M; medial, L; lateral. Scale bar in C
represents 10 μm and applies to panels A-C. LT; Lissauer’s Tract, I; lamina I, IIo; outer lamina II.
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different subpopulations of nociceptive neurons [43,44].
Thus it is possible that peptide release from nociceptors
that may lack significant VGluT2 expression may be
involved in modulation of responses to acute noxious
heat, mechanical and chemical stimuli and heat hyperal-
gesia induced by injury or neuropathic pain. Indeed,
peptide release from nociceptors lacking VGluT2-
expression may also play a role in the so-called
“VGluT2-independent” processes identified in [26], such
as injury induced mechanical allodynia.
Whilst several reports have identified that some pepti-
dergic sensory neurons lack VGluT2-IR in their somata
[26,30] and their terminals [27-31,37,45] there is consid-
erable variation regarding the proportion of peptidergic
neurons this population represents. Whilst different
antibodies were used by Scherrer et al. 2010 [26] and
the present study, the distribution of VGluT2-IR term-
inals in the spinal dorsal horn is remarkably similar in
both studies. It is possible that different strains of mice
have different compositions of nociceptor populations,
as different mouse strains can exhibit considerable dif-
ferences in their response to different types of noxious
stimuli [46]. A systematic study of the colocalisation of
the common nociceptor markers including VGluT2,
CGRP, IB4 and TRPV1 would be required across the
common laboratory mouse strains to examine any rela-
tionship between nociceptor subpopulations and their
phenotypes.
Convergence of primary afferents in lamina I
We have found that putative non-peptidergic glutama-
tergic and peptidergic primary afferent terminals cluster
into partially overlapping domains within lamina I. This
arrangement suggests that separate populations of noci-
ceptors converge onto second order neurons in lamina
I. Indeed, a recent analysis of VGluT2-IR and CGRP-IR
boutons contacting lamina I projection neurons in rat
spinal cord found that many CGRP-IR boutons either
lacked VGluT2-IR or were weakly immunoreactive for
VGluT2 [37]. Pharmacological studies showing disso-
ciated release of glutamate and peptides in the dorsal
horn [43,44] are consistent with these immunohisto-
chemical observations. Electrophysiological evidence
that many lamina I neurons receive convergent C-fiber
and Aδ-fiber nociceptive inputs from different dorsal
root levels [35] implies yet another level of processing of
diverse inputs by lamina I neurons.
Our immunohistochemical methods do not allow the
direct detection of synaptic inputs from different classes
of primary afferents to lamina I neurons. However, at
least some of the Neurobiotin-labeled VGluT2-IR term-
inals must be responsible for fast glutamatergic synaptic
transmission to lamina I neurons. Peptidergic afferents
could communicate with lamina I neurons by non-
synaptic transmission of neuropeptides (volume trans-
mission) as proposed many years ago [47]. If so, spatial
clustering of peptidergic boutons need not necessarily
limit the actions of peptides released from primary affer-
ents to their nearest lamina I neurons.
Most fast transmission from nociceptors to lamina I
neurons appears to be mediated by glutamate [48]. Pep-
tidergic transmission is mediated mainly by substance P
whose actions are facilitated by CGRP [49-51]. Various
genetic and pharmacological manipulations of substance
P-mediated transmission into the dorsal horn suggest
that these peptides mediate only a subset of noxious
sensations [48,52,53]. Indeed, conditional knock-out of
VGluT2 expression in small diameter neurons indicates
that peptides alone probably cannot sustain nociceptive
transmission in the dorsal horn [26].
VGluT2-IR terminals have been found in the skin
[32]. However, the peripheral projections of non-pepti-
dergic VGluT2-IR afferents are not known in detail.
Nevertheless, the co-distribution of their central term-
inals together with CGRP-IR terminals across the dorsal
horn implies that each population of afferents has a
similar somatotopic organization reflecting comparable
peripheral projections [54]. Therefore, when glutamate
and peptides such as substance P and CGRP all contri-
bute to nociceptive responses of lamina I neurons, our
observations suggest two possible pathways: either (1)
all this transmission is mediated by the small proportion
of primary afferents co-expressing peptides and high
levels of VGluT2; or (2) separate populations of non-
peptidergic glutamatergic and peptidergic nociceptors
are co-activated and converge onto common targets in
lamina I. Even if the central terminals of peptidergic
afferents do contribute to glutamatergic nociceptive
transmission, perhaps either underpinned by undetect-
able levels of VGluT2, as recently suggested [26], or
through a novel exocytosis mechanism [55], our data
clearly demonstrate a previously unrecognized level of
organization in lamina I of the dorsal horn consistent
with the presence of multiple nociceptive processing
pathways.
Methods
Anterograde axonal tracing of primary afferent central
terminals
C 5 7 / B l 6m i c e( 8 - 1 0w e e k so l d )w e r ed e e p l ya n a e s t h e -
tized with inhaled isoflurane (Abbott Australasia Pty
Ltd, NSW, Australia) then killed by heart removal. The
lumbar spinal cord and attached dorsal roots were dis-
sected under oxygenated HEPES buffered balanced salt
solution (146 mM NaCl, 4.7 mM KCl, 0.6 mM MgSO4,
1.6 mM NaHCO3,0 . 1 3m MN a H 2PO4,7 . 8m MD - g l u -
cose, 2.5 mM CaCl2, 0.1 mM ascorbic acid, 20 mM
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dorsal roots were either prepared for anterograde axonal
tracing with Neurobiotin in vitro or fixed immediately
and processed for immunohistochemistry. Experiments
were approved by the Animal Welfare Committee of
Flinders University.
For anterograde axonal tracing, the distal ends of dor-
sal roots (single L3 dorsal root, unilateral; all six lumbar
dorsal roots (L1-L6) unilateral plus L3 dorsal root con-
tralateral; or L1-L6 dorsal roots, unilateral) were placed
within internal compartments of a dissecting culture
dish with the attached spinal cord in the outer compart-
ment. The exchange of solutions between compartments
was blocked with petroleum jelly and coverglass barriers.
To aid uptake of the tracer, the distal end of the dorsal
roots were washed three times in Ca
2+ free artificial
intracellular solution (AIS; 7 mM MgCl2,5m MD - g l u -
cose, 1 mM EGTA, 5 mM ATP, 20 mM HEPES, 0.02%
saponin, 1% dimethyl sulfoxide (DMSO), 100 IU/ml
penicillin, 100 μg/ml streptomycin, 10 μg/ml gentami-
cin) and a fresh cut of the distal end(s) performed dur-
ing the first AIS wash. 10-20 μl of 5% Neurobiotin (N-
(2-aminoethyl) biotinamide hydrochloride; Vector
Laboratories, Burlingame, CA) in AIS [56] was applied
to the dorsal roots and covered with paraffin oil. The
HEPES buffered balanced salt solution in the outer com-
partment was replaced with Dulbecco’s modified Eagle
Medium F12 (DMEM/F12) supplemented with 10%
heat-inactivated fetal calf serum, 14.3 mM NaHCO3,2 . 8
mM CaCl2, 100 IU/ml penicillin and 100 μg/ml strepto-
mycin and the preparation incubated in a humidified
cell culture incubator with 5% CO2 at 37°C for 4 hours.
The spinal cord and attached dorsal roots were then
fixed and processed as described below.
Optimisation and assessment of anterograde axonal
tracing using Neurobiotin
Anterograde axonal tracing with Neurobiotin in vitro
was originally developed to identify peripheral projec-
tions of sensory neurons in the gastrointestinal tract
[56]. As this study represents the first reported use of
Neurobiotin to bulk label primary afferent terminals in
mouse spinal cord by anterograde axonal tracing from
the dorsal roots, the technique was carefully optimized
and validated. The optimal incubation time for transport
of Neurobiotin into the spinal dorsal horn was deter-
mined in preliminary experiments. Consequently, 4
hours incubation time was used for definitive experi-
ments as at least 2.5 hours incubation was required to
achieve maximal tracing of fine diameter primary affer-
ents in the dorsal horn, but incubation for more than 6
hours commonly resulted in deterioration of the tissue
with no further increase in the extent of labeling. Com-
parable labeling of primary afferent terminals was seen
with 5% or 1% Neurobiotin. Minor variation in the
extent of tracing of fibers in the dorsal horn was
observed between experiments, presumably due to low
level accidental damage to the nerve roots during the
dissection procedure. The six experiments chosen for
data analysis all showed comprehensive Neurobiotin
transport extending into superficial and deep dorsal
horn laminae across several spinal segments, extending
into the ventral horn at L3. On average, 44.4 ± 4% of
CGRP-IR fibers in the superficial dorsal horn were
labeled with Neurobiotin in these six experiments
(Table 1). As all CGRP-IR terminals in the superficial
dorsal horn are of primary afferent origin, this value is
an indicator of the anterograde tracing efficiency of pri-
mary afferent fibers. There was no evidence of preferen-
tial tracing of CGRP-IR primary afferents compared to
VGluT2-IR primary afferents (see Results).
Tissue processing and immunohistochemistry
Spinal cord segments were fixed for 24-72 hours in
Zamboni’s fixative (2% formaldehyde and 0.5% picric
acid in 0.1 M phosphate buffer, pH 7.0), dehydrated
through a graded series of ethanol, cleared in DMSO
and embedded in polyethylene glycol (MW1450) [57].
Serial transverse 20 μm sections were cut on a rotary
microtome and stored in phosphate-buffered saline
(PBS, pH 7.0) with 0.01% sodium azide. Neurobiotin-
labeled terminals were detected using streptavidin con-
jugated to dichlorotriazinylamino fluorescein (DTAF;
Jackson ImmunoResearch, West Grove, PA). Immuno-
fluorescence was done as previously described using
antibodies to VGluT2 and CGRP which have already
been well characterized in mouse spinal cord (see
below). Sections were preincubated in 10% normal don-
key serum (NDS) for 30 minutes before incubation for
48-72 hours in primary antisera containing 10% NDS.
Primary antisera were washed off in PBS and the sec-
tions incubated overnight in species-specific secondary
antisera raised in donkeys and conjugated to Cy3 and
Cy5 respectively (Jackson ImmunoResearch). In some
sections, the isolectin IB4 (from Griffonia simplicifolia)
conjugated to AlexaFluor488 (code I-21411, Molecular
Probes, Eugene, OR) was included with the primary
antisera, Neurobiotin was detected with streptavidin
conjugated to Cy5 (Jackson ImmunoResearch) and goat
anti-CGRP was detected with donkey anti-goat IgG con-
jugated to aminomethylcoumarin acetate (AMCA; Jack-
son ImmunoResearch). Serial sections were mounted in
0.5 M sodium carbonate-buffered glycerol (pH 8.6) and
coverslips were sealed with nail varnish.
Antibody Characterisation
The primary antibodies used in this study have already
been well characterized for mouse spinal cord. The
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a fusion protein containing glutathione S-transferase
(GST) and amino acid residues 510-582 of rat VGluT2
(catalog number 135 102, Synaptic Systems, Göttingen,
Germany). We have previously demonstrated that label-
ing with this same batch of antibody in mouse spinal
cord was completely abolished by prior incubation with
the control blocking protein, 135-1P (Synaptic Systems,
Göttingen, Germany) [30]. Earlier and subsequent
batches of this polyclonal antibody have been shown to
detect a 65 kD protein in rat brain and spinal cord
extracts in Western blot, with labeling completely
blocked by pre-incubation with the antigen used for the
immunisation [58,59]. Immunolabeling of spinal cord
with this VGluT2 antibody was consistent with other
reported VGluT2 antibodies [24,25,27,29,32] and label-
ing of VGluT2 with the same antibody in rat spinal
cord [28].
The CGRP polyclonal antibody (code number 1780,
Arnel Products Co Inc, New York NY) was raised in
goat against rat CGRP conjugated to gamma globulin.
This antibody has been previously shown not to cross-
react with any known unrelated peptides in sensory and
autonomic ganglia [60] and exhibits labeling consistent
with other reported CGRP antibodies used in guinea-
pig, rat and mouse spinal cord [7,28,30].
Microscopy and image analysis
All images shown and data analyses are from L3 spinal
cord unless otherwise specified. For wide field fluores-
cence microscopy, sections were examined with an
Olympus AX70 epifluorescence microscope (Olympus
Optical Co. Ltd., Tokyo, Japan) fitted with highly discri-
minating filters (Chroma Optical, Brattleboro, VT).
Images were collected using a Hamamatsu Orca cooled
CCD camera (Hamamatsu Photonics, Hamamatsu City,
Japan) connected to a PC running AnalySIS FIVE soft-
ware (v5.0, Olympus Soft Imaging System GmbH, Mün-
ster, Germany).
Identification of regions in the spinal dorsal horn were
identified visually as follows: Lissauer’s Tract; dense
band of axons dorsal to spinal cord, Lamina I, region of
dense CGRP-IR terminals; lamina II; immediately deep
to the predominant band of CGPR-IR in lamina I and
containing a band of IB4-binding terminals (outer
lamina II) and a secondary band of VGluT2-IR term-
inals (inner lamina II), lateral spinal nucleus; lateral to
the lateral boundary of the dorsal horn (marked by lat-
eral border of CGRP-IR), the lateral spinal nucleus is
devoid of CGRP-IR and labels intensely for VGluT2-IR.
ImageJ software (Rasband, 1997-2009) was used to
generate Fast Fourier Transformations (FFT) of images
to create a band-pass spatial filter selectively preserving
low-frequency data representing the dominant spatial
features of labeled terminals in lamina I. The FFT
images were manually edited to produce a low-fre-
quency band pass filter and reverse transformed. 3D
intensity plots of FFT-filtered data were prepared in
ImageJ, from merged images of sections from 3 animals
manually adjusted to correct for variation in dorsal horn
dimensions. Additionally, the spatial coordinates and
sizes of domains derived from FFT-filtered data from 5
consecutive sections from one animal were analysed sta-
tistically after dividing the dorsal horn into medial and
lateral regions. Domain coordinates (center of mass) and
size (area) were obtained from the FFT images in Ima-
geJ, and analysed in SPSS v17 (SPSS Inc, Chicago,
Illinois).
Confocal imaging was done with a Leica TCS SP5
laser scanning confocal microscope and Leica Applica-
tion Suite Advanced Fluorescence software (Leica
Microsystems GmbH, Wetzlar, Germany) in sequential
scanning mode to avoid any chance of signal bleed-
through between channels. Confocal z-stacks, consisting
of 41 optical sections, 0.25 μm apart (total depth of 10
μm), were taken with a 63 × 1.4 N.A. oil immersion
objective and 3× digital zoom with resultant pixel size
of 80 nm. Z-stacks of medial, mid and lateral dorsal
horn were aligned parallel with Lissauer’st r a c ta n dt h e
dorsal-most part of lamina I. At each location, two
further z-stacks were acquired 75 μma n d1 5 0μmv e n -
tral to the lamina I stacks, thereby generating a montage
of three z-stacks spanning from Lissauer’s tract into
lamina III. The z-stacks were analysed with Avizo Fire
software (v5.1.0, Mercury Computer Systems Inc, Mer-
ignac, France) for 3D reconstruction, 3D quantification
and 3D colocalization.
For 3D analysis, data sets from each detection channel
were 3D-median filtered (kernel size 3) to reduce single
pixel noise, thresholds were set to select specific labeling
of nerve terminals above background labeling and the
“exclusive AND” operator was used to determine colo-
calization between the three fluorescence data channels
in x-y-z coordinates. All thresholds were set according
to structural criteria visualising the nerve fibres and
their terminals in 3D and all thresholds were confirmed
to be at least two standard deviations above the mean
intensity value of the background for each respective
fluorescence data channel. Identical thresholds were
used for each of the analysed regions within a spinal
cord section and the respective thresholds for each
channel were verified to be consistent between sections
and between experiments. For each z-stack, data sets
representing the anterogradely-labeled subset of
VGluT2-IR terminals (Neurobiotin and VGluT2-IR
colocalized in 3D), the anterogradely-labeled subset of
CGRP-IR terminals (Neurobiotin and CGRP-IR coloca-
lized in 3D) and the anterogradely-labeled subset of
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(Neurobiotin, VGluT2-IR and CGRP all colocalized in
3D) were calculated from the three original data chan-
nels and designated as new data sets. For illustration
purposes, Neurobiotin-labeled primary afferents are
shown as volume rendered data sets, while subsets of
VGluT2-IR and CGRP-IR terminals (total immunoreac-
tivity and those anterogradely labeled with Neurobiotin)
are displayed with isosurface rendering. Since anterogra-
dely-labeled VGluT2-IR terminals were scarce below the
outer 60 μm of lamina I, quantification was done on a
region of interest (ROI) which extended from the
boundary of Lissauer’s Tract and lamina I to a depth of
60 μm within lamina I (ROI: 80 μm×6 0μm×1 0μm).
The volume of each 3D data set (total anterogradely-
labeled fibers; total and anterogradely-labeled subsets of
VGluT2-IR and CGRP-IR terminals; and the total and
anterogradely-labeled terminals colocalizing both
VGluT2-IR and CGRP-IR) was calculated and exported
into Microsoft Office Excel (Microsoft Coorporation,
US) for further analysis. For comparisons across experi-
ments, volume data were normalized to the maximum
volume of CGRP-IR structures in any of the three ROIs
for each dorsal horn section. Data are displayed as the
mean ± standard error of the mean. Statistical analyses
were done with SPSS.
For analysis of the spatial arrangement of VGluT2-IR
and CGRP-IR terminals, z-stacks were processed in
Avizo Fire software. Data which had been 3D median-
filtered, thresholded and analysed for 3D colocalization
as described above were further processed by an “Open-
ing” operand to enable separation of adjoining terminals
into discrete entities. The x-y-z coordinates of the cen-
ter of mass of each derived structure, along with its cor-
responding volume, were computed in Avizo Fire and
their spatial distributions were analysed in SPSS with
hierarchical cluster analysis, using 10-20 cluster seeds.
The cluster analyses used both weighted coordinates
(adjusted by volume for the different number of term-
inals represented in each 3D structure) and unweighted
coordinates in 3D (x-y-z coordinates) and in 2D (x-y
coordinates). Each cluster was then analysed to deter-
mine if it contained more CGRP-IR or VGluT2-IR term-
inals than would be expected by chance using X
2
statistics and analysis of residuals. One complete data
set from each dorsal horn location (medial, mid and lat-
eral regions of lamina I) was analysed in this way.
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